AveXis, Inc. (AVXS) Holdings Cut by Iguana Healthcare Management LLC
Iguana Healthcare Management LLC trimmed its stake in shares of AveXis, Inc. (NASDAQ:AVXS) by 41.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 12,500 shares during the period. Iguana Healthcare Management LLC owned 0.05% of AveXis worth $1,693,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of AVXS. Strs Ohio purchased a new position in AveXis during the third quarter valued at $116,000. Botty Investors LLC purchased a new position in AveXis during the second quarter valued at $123,000. Ameritas Investment Partners Inc. lifted its holdings in AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of AveXis in the third quarter worth about $200,000. 92.88% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $173,105. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by company insiders.
Shares of AveXis, Inc. (NASDAQ:AVXS) opened at $98.34 on Thursday. AveXis, Inc. has a 12-month low of $44.68 and a 12-month high of $108.27.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period in the previous year, the business posted ($0.87) EPS. equities analysts predict that AveXis, Inc. will post -6.23 earnings per share for the current year.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Stock Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related stocks with our FREE daily email newsletter.